Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triamcinolone peri-articular injection during total knee arthroplasty for knee arthritis
ACTRN12609000345280Phase 4Not yet recruiting
- Sponsor
- Samchia Biotech
- Start
- Jun 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of triamcinolone acetonide in knee osteoarthritis (OA) and knee arthritis (3 arms), sponsored by Samchia Biotech. Primary endpoints: Knee injury and osteoarthritis outcome score, Knee range of motion and 1 more. Planned start Jun 2009; status: not yet recruiting.
02
Drugs
triamcinolone acetonide
03
Conditions
knee osteoarthritis (OA)knee arthritis
Beyond the preview
Go deeper on ACTRN12609000345280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12609000345280.